| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2026 | 31 Jan 2026 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter and nine months ended on 31st December 2025. Outcome of Board Meeting held on 13th February, 2026 Approval of Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (As Per BSE Announcement Dated on:13.02.2026) | ||
| Board Meeting | 13 Nov 2025 | 8 Nov 2025 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter and half year ended on 30th September 2025. Outcome of Board Meeting Outcome of Board Meeting (As Per BSE Announcement Dated on:13.11.2025) | ||
| Board Meeting | 8 Aug 2025 | 4 Aug 2025 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 inter alia to consider and approve approval of un-audited (Standalone & Consolidated) Financial Results for the quarter ended on 30th June 2025. Outcome of Board Meeting (As Per BSE Announcement Dated on:08.08.2025) | ||
| Board Meeting | 4 Jun 2025 | 4 Jun 2025 |
| Intimation of Appointment of Additional Director (Non Executive- Independent) | ||
| Board Meeting | 26 May 2025 | 19 May 2025 |
| Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve Un-audited (Standalone & Consolidated) Financial Results for the quarter ended on 31st March 2025 and Audited (Standalone & Consolidated) Financial statements for the year ended on 31st March 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 26.05.2025) | ||
The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
